The Cost-effectiveness of Artificial Intelligence Acute Kidney Injury Prediction Auxiliary Software (Acura AKI)

Launched by HUEDE HEALTHTECH CO., LTD. · Nov 10, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new software called Acura AKI, which uses advanced technology to predict the risk of Acute Kidney Injury (AKI) in patients in intensive care units (ICUs). The goal is to see if using this software can help doctors identify patients at high risk for kidney problems early on, allowing for better care and potentially improving their health outcomes. The study will measure how effective and cost-efficient this tool is by tracking things like how many patients develop AKI, how many need dialysis (a treatment for kidney failure), overall survival rates, and how long patients stay in the hospital.

To participate in the trial, patients must be over 20 years old, be admitted to an adult ICU, and expect to stay in the hospital for more than 30 hours. However, those who already have AKI, are on dialysis, or have certain other medical conditions won't be eligible. Participants will be monitored to see how well the Acura AKI software works in predicting kidney issues during their hospital stay. This study is actively recruiting participants, and it offers a chance to contribute to important research that could improve future care for critically ill patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Over 20 years old
• • Admitted to adult ICU
• • Hospital stay of more than 30 hours
• Exclusion Criteria:
• • Known to have acute kidney injury at enrollment
• • Currently undergoing hemodialysis treatment
• • No available blood or urine test data
• • Pregnant women
• • HIV-positive patients
• • Those who have not provided informed consent form
• • Regarded as unsuitable for inclusion in the trial by the researcher